Terms: = Endocrine gland cancer AND SYK, P43405, 6850, ENSG00000165025 AND Treatment
10 results:
1. Spleen tyrosine kinase facilitates the progression of papillary thyroid cancer regulated by the hsa_circ_0006417/miR-377-3p axis.
Tan G; Zheng S; Zhou B; Mo Z; Zhang Q; Zhang D; Li A; Liu X
Environ Toxicol; 2024 Jan; 39(1):421-434. PubMed ID: 37792549
[TBL] [Abstract] [Full Text] [Related]
2. syk Inhibition Reprograms Tumor-Associated Macrophages and Overcomes Gemcitabine-Induced Immunosuppression in Pancreatic Ductal Adenocarcinoma.
Rohila D; Park IH; Pham TV; Weitz J; Hurtado de Mendoza T; Madheswaran S; Ishfaq M; Beaman C; Tapia E; Sun S; Patel J; Tamayo P; Lowy AM; Joshi S
Cancer Res; 2023 Aug; 83(16):2675-2689. PubMed ID: 37306759
[TBL] [Abstract] [Full Text] [Related]
3. Special issue "The advance of solid tumor research in China": Prediction of Sunitinib efficacy using computed tomography in patients with pancreatic neuroendocrine tumors.
Chen L; Wang W; Jin K; Yuan B; Tan H; Sun J; Guo Y; Luo Y; Feng ST; Yu X; Chen MH; Chen J
Int J Cancer; 2023 Jan; 152(1):90-99. PubMed ID: 36111424
[TBL] [Abstract] [Full Text] [Related]
4. Extracellular microRNA profiling for prognostic prediction in patients with high-grade serous ovarian carcinoma.
Yoshida K; Yokoi A; Matsuzaki J; Kato T; Ochiya T; Kajiyama H; Yamamoto Y
Cancer Sci; 2021 Dec; 112(12):4977-4986. PubMed ID: 34618992
[TBL] [Abstract] [Full Text] [Related]
5. Transcriptome sequencing identifies genes associated with invasion of ovarian cancer.
Peng X; Yu M; Chen J
J Int Med Res; 2020 Sep; 48(9):300060520950912. PubMed ID: 32878513
[TBL] [Abstract] [Full Text] [Related]
6. The syk inhibitor R406 is a modulator of P-glycoprotein (ABCB1)-mediated multidrug resistance.
Duran GE; Sikic BI
PLoS One; 2019; 14(1):e0210879. PubMed ID: 30668583
[TBL] [Abstract] [Full Text] [Related]
7. Induction of galectin-1 by TLR-dependent PI3K activation enhances epithelial-mesenchymal transition of metastatic ovarian cancer cells.
Park GB; Chung YH; Kim D
Oncol Rep; 2017 May; 37(5):3137-3145. PubMed ID: 28350104
[TBL] [Abstract] [Full Text] [Related]
8. Evaluation of atherosclerosis after cessation of cabergoline therapy in patients with prolactinoma.
Doğan BA; Arduç A; Tuna MM; Nasıroğlu NI; Işık S; Berker D; Güler S
Anatol J Cardiol; 2016 Jun; 16(6):440-7. PubMed ID: 26680550
[TBL] [Abstract] [Full Text] [Related]
9. Inhibition of Spleen Tyrosine Kinase Potentiates Paclitaxel-Induced Cytotoxicity in Ovarian cancer Cells by Stabilizing Microtubules.
Yu Y; Gaillard S; Phillip JM; Huang TC; Pinto SM; Tessarollo NG; Zhang Z; Pandey A; Wirtz D; Ayhan A; Davidson B; Wang TL; Shih IeM
Cancer Cell; 2015 Jul; 28(1):82-96. PubMed ID: 26096845
[TBL] [Abstract] [Full Text] [Related]
10. Oncoproteomic analysis reveals co-upregulation of RELA and STAT5 in carboplatin resistant ovarian carcinoma.
Jinawath N; Vasoontara C; Jinawath A; Fang X; Zhao K; Yap KL; Guo T; Lee CS; Wang W; Balgley BM; Davidson B; Wang TL; Shih IeM
PLoS One; 2010 Jun; 5(6):e11198. PubMed ID: 20585448
[TBL] [Abstract] [Full Text] [Related]
